Developing Therapeutics for Alzheimer's Disease

Michael S. Wolfe is the Mathias P. Mertes Professor of Medicinal Chemistry at the University of Kansas. He received his B.S. in chemistry in 1984 from the Philadelphia College of Pharmacy and Science and Ph.D. in medicinal chemistry in 1990 from the University of Kansas. After postdoctoral stints at the University of Kansas (medicinal chemistry) and the NIH (cell biology), he joined the faculty of the University of Tennessee in Memphis in 1994. In 1999, he joined the faculty at Brigham and Women’s Hospital and Harvard Medical School in Boston, becoming Professor of Neurology in 2008. Prof. Wolfe’s work has focused on understanding the molecular basis of Alzheimer’s disease and related disorders, and identifying effective approaches for pharmacological intervention. Awards for his work include the Sato Memorial International Award in bioorganic and medicinal chemistry from the Pharmaceutical Society of Japan (2003), the MetLife Award for Biomedical Research (2008), a Zenith Fellows Award from the Alzheimer’s Association (2008), and the Potamkin Prize from the American Academy of Neurology (2009).

1. The Complex Pathways to Mechanism-Based Therapeutics in Alzheimer’s Disease
2. The Genetic Basis of Alzheimer's Disease
3. B-Secretase Inhibition
4. Y-Secretase Inhibitors: from Chemical Probes to Drug Development
5. Therapeutic Targeting of AB42
6. Modulators of Amyloid B-Protein (AB) Self-Assembly
7. Anti-Amyloid-B Immunotherapy for Alzheimer’s Disease
8. Targeting AB Receptors to Modify Alzheimer’s Disease Progression
9. Blood-Brain Barrier Transport of Alzheimer’s Amyloid B-Peptide
10. Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
11. Microtubule Stabilization
12. Tau Phosphorylation as a Therapeutic Target in Alzheimer's Disease
13. Stimulation of Tau Degradation
14. Passive Immunotherapy for Tau Pathology
15. Inhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer’s Disease
16. Neuroprotective Strategies for Alzheimer’s Disease Prevention and Therapy
17. Symptomatic Cognitive Enhancing Agents
18. Tackling Alzheimer's Disease by Targeting Oxidative Stress and Mitochondria
19. Preclinical and Clinical Issues in Alzheimer Drug Development
20. Molecular Imaging in Alzheimer Clinical Trials
21. Fluid Biomarkers and Diagnostics
22. Non-Pharmacologic Activity Interventions to Prevent Alzheimer’s Disease
23. Prospects and Challenges for Alzheimer Therapeutics